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Abstract: Patients with the 15q11.2 BP1–BP2 microdeletion can present with developmental 
and language delay, neurobehavioral disturbances and psychiatric problems. Autism, 
seizures, schizophrenia and mild dysmorphic features are less commonly seen. The 
15q11.2 BP1–BP2 microdeletion involving four genes (i.e., TUBGCP5, CYFIP1, NIPA1, 
NIPA2) is emerging as a recognized syndrome with a prevalence ranging from  
0.57%–1.27% of patients presenting for microarray analysis which is a two to four fold 
increase compared with controls. Review of clinical features from about 200 individuals 
were grouped into five categories and included developmental (73%) and speech (67%) 
delays; dysmorphic ears (46%) and palatal anomalies (46%); writing (60%) and reading 
(57%) difficulties, memory problems (60%) and verbal IQ scores ≤75 (50%); general 
behavioral problems, unspecified (55%) and abnormal brain imaging (43%). Other clinical 
features noted but not considered as common were seizures/epilepsy (26%), autism 
spectrum disorder (27%), attention deficit disorder (ADD)/attention deficit hyperactivity 
disorder (ADHD) (35%), schizophrenia/paranoid psychosis (20%) and motor delay (42%). 
Not all individuals with the deletion are clinically affected, yet the collection of findings 
appear to share biological pathways and presumed genetic mechanisms. Neuropsychiatric 
and behavior disturbances and mild dysmorphic features are associated with genomic 
imbalances of the 15q11.2 BP1–BP2 region, including microdeletions, but with an apparent 
incomplete penetrance and variable expressivity.  
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1. Introduction 
Chromosome 15 contains five common breakpoint sites along the proximal long arm; they are 
commonly referred to as BP1–BP5. There is a cluster of low copy DNA repeats located within this 
chromosome region which can facilitate mis-alignment during meiosis leading to non-allelic 
homologous recombination [1,2]. These low copy repeat sequences are called duplicons and contain 
pseudogenes [3]. Duplicons found within breakpoints BP1, BP2 and BP3 have been characterized by 
the presence of the HERC2 gene (at BP3) and HERC2 pseudogenes (at BP1 and BP2) [2]. 
Prader-Willi syndrome (PWS) and Angelman syndrome are typically caused by a deletion of 
different parental origin involving the distal breakpoint BP3 and proximally placed breakpoints BP1 or 
BP2. These cytogenetic deletions of chromosome 15q11–q13 region are classified as typical type I 
(involving BP1 and BP3) or typical type II (involving BP2 and BP3) (see Figure 1). Type I deletions 
have an average genomic length of 6.58 Mb while type II deletions have a mean length of 5.33 Mb [4]. 
Several studies have shown that individuals with the larger typical 15q11–q13 type I deletion which  
is found in both Prader-Willi and Angelman syndromes are reported to have more severe 
neurodevelopmental symptoms as compared to those individuals with the smaller typical type II 
deletion [5–10]. Initially, Butler et al. [5] found that several behavioral and intelligence measures were 
statistically different between the two PWS deletion types (type I and type II). PWS individuals  
with type I deletions showed more compulsive and self-injurious behaviors and visual perception 
impairment along with lower intelligence, reading and math scores than in those with type II deletions. 
Furthermore, Bittel et al. [6] reported that the amount of mRNA isolated from lymphoblastoid cell 
lines established from individuals with PWS for the four genes (i.e., NIPA1, NIPA2, CYFIP1, 
TUBGCP5) found in the genomic area between BP1 and BP2 in the 15q11.2 chromosome band 
explained between 24% to 99% of the phenotypic variability in behavioral and academic measures. 
The NIPA2 gene accounted for the largest number of significant correlations between the mRNA 
levels and phenotypic features. 
In other studies, Varela et al. [10] found that individuals with PWS having 15q11–q13 type I 
deletions acquired speech later than those with type II deletions. Hartley et al. [7] also found that 
individuals with PWS having type I deletions had significantly higher Reiss maladaptive behavior 
scores for depression (physical signs) than individuals with type II deletions. Similarly, Sahoo et al. [9] 
reported that in individuals with Angelman syndrome and the 15q11–q13 type I deletion had 
significantly more behavioral and cognitive impairments with lower expressive and total language 
abilities and a higher likelihood of features for autism spectrum disorder.  




Figure 1. High resolution ideogram representing chromosome 15 showing location of 
breakpoints BP1 and BP2 (at 15q11.2 band) and BP3 (at 15q13.1 band) involving HERC2 
and position of the non-imprinted genes between BP1 and BP2. The three deletion types 
involving the 15q11–q13 region (i.e., BP1–BP2, typical type I, typical type II) are represented. 
Valente et al. [11] also reported in Angelman syndrome that those with the 15q11–q13 type I 
deletion had more severe seizures and were refractory to treatment compared with those having the 
type II deletion. In a separate study Milner et al. [8] found significantly higher verbal IQ scores in 
individuals with PWS and type II deletions versus those with type I deletions. They further reported 
that those with type I deletions performed more poorly on all measures of ability even though they 
were not significantly different from the patients with type II deletions.  
A report by Dykens and Roof [12] examined behaviors in PWS using a mixed cohort of young and 
old subjects (n = 88) and showed a relationship between genetic subtypes and ages. They found 
negative associations between age and behavior in the 15q11–q13 type I deletion subtype only which 
implicated non-imprinted genes between breakpoints BP1 and BP2, specifically the CYFIP1 gene. 
Disturbed expression of CYFIP1 is seen in other developmental disabilities including those with 15q 
disorders without PWS. Although they reported no significant behavioral findings when combining 
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data from subjects at all ages, significant differences were found in those with type I versus type II 
deletions with age. The individuals with the 15q11–q13 type I deletion consistently had lower targeted 
problem behaviors and adaptive skills and externalizing symptoms with advancing age. 
As several studies have shown evidence of disturbed gene expression patterns and behavioral 
findings in subjects with either PWS or Angelman syndrome with different genetic deletion subtypes 
implicating genes within the BP1 and BP2 genomic region, Burnside et al. [13] summarized the 
literature and surveyed the first large cohort of patients presenting for genetic testing using high 
resolution microarrays. They found that 0.86% of the approximate 17,000 individuals had an 
abnormality (deletion or duplication) of the 15q11.2 BP1–BP2 region. Specifically, 69 subjects were 
found with the 15q11.2 microdeletion and 77 subjects were found with a microduplication of the same 
region. They proposed that this genomic area was a susceptibility region for neurological dysfunction, 
impaired development and characteristic phenotypic features which was initially raised by Butler et al. [5] 
in a study of PWS individuals with the larger 15q11–q13 type I deletion including the four genes in  
the BP1 and BP2 area and having a more severe behavior phenotype compared with those with the 
smaller type II deletion. Collectively, they summarized that a deletion involving this genomic region 
correlated with language or motor delays, behavioral problems, autism, seizures and occasionally mild 
dysmorphic features. The collection of clinical findings in the microdeletion in a large cohort of patients 
with the 15q11.2 BP1–BP2 presenting for genetic services supported the original observations by  
Butler et al. [14] of behavioral disturbances seen in PWS patients with the larger 15q11–q13 type I 
deletion compared with the smaller type II deletion which stimulated interest in additional studies of 
this chromosome region and, hence, coined the Burnside-Butler syndrome.  
Preliminary clinical information about the 15q11.2 microdeletion alone without PWS was first 
reported by Murthy et al. [15] in 2007 in two individuals in a consanguineous family and later  
by Doornbos et al. [16] in 2009 in nine individuals. The vast majority of their combined subjects 
presented with behavioral or neurological problems. Later, Abdelmoity et al. [17] reported a cohort of 
1654 consecutive pediatric patients presenting with a range of neurological disorders and found that 
21% or 1.27% of the patients carried a 15q11.2 BP1–BP2 deletion. They found that 87.5% of the patients 
with the deletion had developmental delay or intellectual disability. More recently, Cafferkey et al. [18] 
presented data from 14,605 patients (primarily pediatric) referred for genetic testing using  
microarray analysis and found 83 (0.57%) with the 15q11.2 BP1–BP2 microdeletion. The majority  
of their patients presented with some form of behavioral disturbance or developmental/motor delays  
as summarized by Burnside et al. [13]. The area between BP1 and BP2 is approximately 500 kb in size 
and includes the NIPA1, NIPA2, TUBGCP5, and CYFIP1 genes and prone to both microdeletions  
and microduplications. In this review, we summarize information regarding the 15q11.2 BP1–BP2 
microdeletion. A review of information regarding the microduplication is beyond the scope of this report.  
Chai et al. [19] showed that these four genes are highly conserved and biallelically expressed. 
NIPA1 or non-imprinted in Prader-Willi/Angelman syndrome 1 gene is the best studied gene within 
this region and associated with autosomal dominant hereditary spastic paraplegia [20,21]. There has 
been no case to date where haploinsufficiency of NIPA1 due to a deletion has led to hereditary spastic 
paraplegia. NIPA1 also mediates Mg2+ transport and is highly expressed in neuronal tissue [22]. The 
NIPA2 or non-imprinted in Prader-Willi/Angelman syndrome 2 gene is used in renal Mg2+ transport [22]. 
Jiang et al. [23] examined patients with childhood absence epilepsy and found mutations in NIPA2 
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with unknown functional effects. The TUBGCP5 gene or tubulin gamma complex associated protein 5 
gene is involved in neurobehavioral disorders including ADHD and OCD [24]. The final gene within 
this region is CYFIP1 or cytoplasmic fragile X mental retardation 1 (FMR1) interacting protein 1 gene. 
This gene product interacts with FMRP in a ribonucleoprotein complex. FMRP is the product of  
the FMR1 gene which is associated with fragile X syndrome, the most common cause of familial 
intellectual disability that primarily affects males [25]. Both of these gene products play important 
roles in the regulation of brain mRNAs [24]. Bozdagi et al. [26] showed that haploinsufficiency of 
CYFIP1 resembles important aspects found in knockout FMR1 mice.  
Not all individuals with defects within the 15q11.2 band (i.e., microdeletions or microduplications) 
share a clinical phenotype or are clinically affected. Therefore, this region contains genetic material 
showing incomplete penetrance or low penetrance of pathogenicity along with variable expressivity.  
For example, a review of reported data from control cohorts (n = 66,462 subjects) summarized to date 
show that about 0.25% of controls are found with the 15q11.2 BP1–BP2 microdeletion [18,27–31]. 
The penetrance of the 15q11.2 BP1–BP2 microdeletion has also been estimated at 10.4% [28]  
or an approximate two fold increase over the general population risk but may be due to paucity of 
inheritance data. Other estimates have been lower but results consistently show this region to play  
a role in autism [32]. The penetrance for the 15q11.2 microdeletion is low compared to other 
microdeletion syndromes such as the 16p11.2 deletion with a penetrance estimated at 62.4% [28].  
A higher penetrance is often seen in copy number variants (CNVs) that have higher de novo 
frequencies while low penetrance estimates may reflect a subclinical presentation or manifestation of 
features that are recognized as components of disorders such as neuropsychiatric disturbances in 
parents of affected individuals (e.g., autism in 15q11.2 BP1–BP2 deletion) or in control cohorts. Not 
only are microarray studies needed on other family members (and parents) of those with the 15q11.2 
BP1–BP2 deletion but also neuropsychiatric and behavioral testing as well to appreciate the variability 
of expression and level of penetrance. The review of literature from six published reports summarized 
by Cafferkey et al. [18] regarding information on the inheritance of the 15q11.2 BP1–BP2 
microdeletion indicates that 22/43 (51%) of individuals with the microdeletion, where parental data 
were available, inherited their deletion from an apparently healthy parent while 10/29 (35%) of 
individuals inherited their deletion from an abnormal parent [13,15–17,33,34]. The phenotypic 
information was unavailable or incomplete for all parents found to carry the deletion. The reported  
de novo deletion frequency ranged from 1/21 (5%) [13] to 2/9 (22%) [16] in subjects reviewed by 
Cafferkey et al. [18]. It would be of importance to undertake DNA sequencing analyses of the 15q11.2 
BP1–BP2 genomic region to identify subtle deletions or mutations of the non-deleted allele and 
determine the genetic status of this “normal allele”. Other modifying genes outside of the chromosome 
region may also play a role and will require further investigations.  
Recently, individuals have been reported with the 15q11.2 BP1–BP2 microdeletion and additional 
non-neurological clinical findings. These findings included congenital cataracts [14,35], proximal 
esophageal atresia and distal tracheoesophageal fistula (type C) [35] and congenital arthrogryposis [36]. 
These clinical reports lend support for further phenotypic expansion of this susceptibility region 
impacted by the 15q11.2 BP1–BP2 microdeletion. Our report will focus on the review of the clinical 
features now recognized in this microdeletion syndrome.  
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2. Results and Discussion 
2.1. Growth and Development  
A review of the literature on growth and development in individuals with 15q11.2 BP1–BP2 
microdeletions involving a susceptibility region for neurological dysfunction with general 
developmental and motor delay with speech problems as primary components of this disorder. General 
developmental delay occurred in 73% of individuals and speech delay occurred in 67% as reported  
in the literature suggesting characteristic features for this microdeletion syndrome (see Table 1). These 
features may correlate with the neuronal components of the genes within this deleted region. NIPA1, 
NIPA2, and CYFIP1 are highly expressed in neuronal tissue of the central nervous system and 
TUBGCP5 is highly expressed in the subthalamic nuclei [22,24].  
Motor delay and microcephaly were considered important features of this microdeletion syndrome 
after a review of the literature. Motor delay was seen in 42% of individuals and microcephaly was seen 
in 24%. Occasional features found were intrauterine growth retardation (18%), short stature (10%), 
and macrocephaly (8%) (see Table 1). 
2.2. Dysmorphic Features 
A review of the literature on the dysmorphic features for those individuals with the 15q11.2 BP1–BP2 
microdeletion or Burnside-Butler syndrome showed that this disorder does not appear to have a clear 
dysmorphic phenotype (see Table 2). This is supported by studies by Butler et al. [5] in examining 
individuals with Prader-Willi syndrome with 15q11–q13 type I deletion or type II deletion and 
observing behavioral and cognitive differences but not in growth parameters or other clinical findings 
indicating that the four genes present within the BP1–BP2 genomic area and when disturbed can lead 
to neurological or behavioral outcomes.  
2.3 Intelligence and Academic Achievement  
General, non-specified, dysmorphic features were seen in 55 out of 141 individuals or 39% of  
those reported within the literature. The only common dysmorphic feature found from a review of  
the literature was palatal abnormalities with 46% of individuals being reported with these findings. 
Occasional dysmorphic features included broad forehead (21%), hypertelorism (18%), slender fingers 
(15%), pectus excavatum (13%), plagiocephaly (10%), dysmorphic nose (8%), dysmorphic teeth (8%), 
and contractures/arthrogryposis (8%). Reported dysmorphic features that, at present, are uncommon or 
not associated with this syndrome based on a literature review and include short fingers (5%), long 
narrow face (3%), small face (3%), and hypotelorism (3%) (see Table 2). 
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et al. [16] 
Von der Lippe 
et al. [34] 
Burnside 
et al. [13] 
Abdelmoity 
et al. [17] 
Madrigal 
et al. [33] 
Wong  
et al. [35] 
Cafferkey 
et al. [18] 
Usrey  
et al. [36] 
Rudd  




IUGR 1 0/1 3/9 0/5 N/A N/A N/A 1/2 N/A 0/2 0/2 0/1 4/22 (18) 
Short stature 0/1 1/9 1/5 N/A N/A N/A 0/2 N/A 0/2 N/A 0/1 2/20 (10) 
Microcephaly 0/1 1/9 0/5 N/A 4/16 2/2 0/2 N/A 1/2 N/A 1/1 9/38 (24) 
Macrocephaly 0/1 0/9 1/5 N/A 2/16 0/2 0/2 N/A 0/2 N/A 0/1 3/38 (8) 
Developmental 
delay (general) 
2/2 7/8 4/7 33/56 13/15 * 2/2 0/2 65/77 N/A 0/2 0/1 126/172 (73) 
Motor delay 1/2 8/9 5/7 20/56 N/A 2/2 1/2 29/77 N/A 0/2 0/1 66/158 (42) 
Speech delay 2/2 8/8 5/5 44/49 N/A 2/2 0/2 37/77 N/A 0/2 1/1 99/148 (67) 
1 Intrauterine growth retardation; * indicated both Intellectual disability or Global developmental delay; Bold indicate categories that represent 50% or greater incidence 
within the literature. 
Table 2. Literature Review of Dysmorphic Features for Individuals with Chromosome 15q11.2 BP1–BP2 Microdeletion Syndrome. 
Feature 
Doornbos  
et al. [16] 
Von der Lippe 
et al. [34] 
Burnside 
et al. [13] 
Abdelmoity 
et al. [17] 
Madrigal 
et al. [33] 
Wong  
et al. [35] 
Cafferkey 
et al. [18] 
Usrey  
et al. [36] 
Rudd  




Dysmorphism, unspecified N/A N/A 27/56 N/A N/A N/A 28/83 N/A 0/2 N/A 55/141 (39) 
Plagiocephaly 4/9 0/7 N/A 0/16 0/2 0/2 N/A 0/2 N/A 0/1 4/39 (10) 
Broad forehead 5/9 0/7 N/A 1/16 2/2 0/2 N/A 0/2 N/A 0/1 8/39 (21) 
Long narrow face 0/9 1/7 N/A 0/16 0/2 0/2 N/A 0/2 N/A 0/1 1/39 (3) 
Small face 0/9 1/7 N/A 0/16 0/2 0/2 N/A 0/2 N/A 0/1 1/39 (3) 
Hypertelorism 5/9 1/7 N/A 1/16 0/2 0/2 N/A 0/2 N/A 0/1 7/39 (18) 
Hypotelorism 0/9 1/7 N/A 0/16 0/2 0/2 N/A 0/2 N/A 0/1 1/39 (3) 
Abnormal nose 0/9 2/7 N/A 1/16 0/2 0/2 N/A 0/2 N/A 0/1 3/39 (8) 
Dysmorphic ears 6/9 0/7 N/A 1/16 2/2 0/2 N/A 0/2 N/A 1/1 9/39 (46) 
Palatal abnormalities 4/9 0/7 N/A 2/16 2/2 1/2 N/A 0/2 N/A 0/1 9/39 (46) 
Abnormal teeth 0/9 2/7 N/A 1/16 0/2 0/2 N/A 0/2 N/A 0/1 3/39 (8) 
Pectus excavatum 2/9 0/7 N/A 1/16 0/2 1/2 N/A 0/2 N/A 1/1 5/39 (13) 
Contractures/arthrogryposis 0/9 1/7 N/A 0/16 0/2 0/2 N/A 2/2 N/A 0/1 3/39 (8) 
Short fingers 0/9 1/7 N/A 1/16 0/2 0/2 N/A 0/2 N/A 0/1 2/39 (5) 
Slender fingers 5/9 1/7 N/A 0/16 0/2 0/2 N/A 0/2 N/A 0/1 6/39 (15) 
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Intelligence and academic achievement for individuals with 15q11.2 BP1–BP2 microdeletions were 
reviewed (see Table 3). Common reported features included writing difficulties (60%), memory 
problems (60%), reading difficulties (57%), and a verbal IQ score equal to or below 75 (50%). 
However, very few individuals were reported within the literature regarding these findings so further 
studies are needed to determine if they are associated findings. Occasional findings within the 
literature included intellectual disability (37%) and performance IQ which was equal to or below 75 
(33%). There were 43 out of 116 individuals reported within the literature who had intellectual 
disability; however, there were only 1 out of 3 individuals reportedly with a low performance IQ. 
Stefansson et al. [38] found a modest effect on verbal IQ (effect = 0.38, p = 0.033) and performance IQ 
(effect = 0.43, p = 0.018) from the 15q11.2 deletion. 
2.4. Behavioral and Psychiatric Problems 
Behavioral features including autism spectrum disorder and schizophrenia have been studied as 
features of the 15q11.2 BP1–BP2 microdeletion [32,33,37–40]. A review of the behavioral and 
psychiatric features reported within the literature found that 55% of those reported had general behavior 
problems that were not otherwise specified (see Table 4). Common behavioral features included 
Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder (35%), Autism Spectrum Disorder 
(27%), obsessive compulsive disorder (26%), self-injurious behaviors (26%), oppositional defiant 
disorder (24%), and schizophrenia or paranoid psychosis (20%). Studies have been performed to 
determine if the 15q11.2 BP1–BP2 microdeletion is a susceptibility locus for schizophrenia [37–40]. 
Rees et al. [40] found a significant association between the microdeletion and schizophrenia with the 
frequency of individuals having schizophrenia and the microdeletion from their study was 0.64 
(44/6882). The 15q11.2 BP1–BP2 microdeletion has also been studied regarding potential susceptibility 
for autism [32]. Chaste et al. [32] found a small risk regarding this microdeletion and autism but a greater 
effect on the autism phenotype in males and when maternally inherited. They reported an overall modest 
effect for this copy number variant for autism in studying a sample of 2525 families with autism [32]. 
They suggested that carriers may need additional copy number variants along with the 15q11.2 
microdeletion in order to be diagnosed with autism [32]. Occasionally, reported behavioral features 
within the literature included an unusually happy expression (12%) and anxiety (6%) [16,34]. 
2.5. Other Related Medical Concerns 
The 15q11.2 BP1–BP2 microdeletion or Burnside-Butler syndrome has been reported with various 
medical concerns or conditions (see Table 5). A review of the literature indicated that 43% of these 
individuals had abnormal brain imaging (MRI, EEG, etc.) with common clinical features of seizures or 
epilepsy (26%) and ataxia or balance (coordination) problems (28%). The medical literature 
surrounding this microdeletion syndrome and seizures indicate that this chromosomal anomaly may be 
a risk factor for epilepsy [29,41–43]. Occasional features seen within the literature regarding medical 
conditions included congenital heart defect (9%), genital abnormalities (7%), recurrent infections 
(7%), cataracts (4%), hearing loss or impairment (4%), tracheoesophageal fistula (2%), and 
omphalocele (2%). Whether these additional findings represent further phenotypic expansion of the 
syndrome as raised by others is unknown [14,35,36]. 
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et al. [15] 
Doornbos 
et al. [16] 
De Kovel 
et al. [29] 
Von der Lippe 
et al. [34] 
Burnside 
et al. [13] 
Abdelmoity 
et al. [17] 
Madrigal 
et al. [33] 
Mullen 
et al. [43] 
Jahn  
et al. [42] 
Usrey  
et al. [36] 
Rudd  




ID */FSIQ 1 ≤ 
75/special 
education 
2/2 6/12 0/11 5/11 11/49 13/15 2/2 1/6 2/3 1/1 0/3 0/1 
43/116 
(37) 
Verbal IQ  
≤ 75 
N/A 1/1 N/A N/A N/A N/A N/A N/A N/A N/A 1/3 N/A 2/4 (50) 
Performance 
IQ ≤ 75 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 1/3 N/A 1/3 (33) 
Reading 
difficulties 
N/A N/A N/A 4/7 N/A N/A N/A N/A N/A N/A N/A N/A 4/7 (57) 
Writing 
difficulties 
N/A N/A N/A 3/5 N/A N/A N/A N/A N/A N/A N/A N/A 3/5 (60) 
Memory 
problems 
N/A N/A N/A 2/4 N/A N/A N/A N/A N/A N/A N/A 1/1 3/5 (60) 
* Intellectual disability; 1 Full scale intelligence quotient; Bold indicate categories that represent 50% or greater incidence within the literature. 
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et al. [15] 
Doornbos 
et al. [16] 
Von der Lippe 
et al. [34] 
Burnside 
et al. [13] 
Abdelmoity 
et al. [17] 
Madrigal 
et al. [33] 
Cafferkey 
et al. [18] 
Rudd  






2/2 N/A N/A 35/56 N/A 2/4 35/73 N/A 1/1 75/136 (55) 
Autism Spectrum Disorder 1/2 4/9 1/7 14/49 2/16 2/4 19/73 N/A 0/1 43/161 (27) 
Schizophrenia/paranoid 
psychosis 
N/A 0/9 1/7 N/A N/A N/A N/A 3/3 0/1 4/20 (20) 
OCD 1 0/2 2/9 0/7 16/49 * N/A N/A N/A N/A 0/1 18/68 (26) 
ODD 2 0/2 0/9 0/7 16/49 * N/A N/A N/A N/A 0/1 16/68 (24) 
ADD 3/ADHD 4 2/2 2/9 0/7 16/49 7/12 N/A N/A N/A 1/1 28/80 (35) 
Self-injurious behaviors 0/2 2/9 0/7 16/49 * N/A N/A N/A N/A 0/1 18/68 (26) 
Anxiety N/A 0/9 1/7 N/A N/A N/A N/A N/A 0/1 1/17 (6) 
Happy expression N/A 2/9 0/7 N/A N/A N/A N/A N/A 0/1 2/17 (12) 
1 Obsessive compulsive disorder; 2 Oppositional defiant disorder; 3 Attention deficit disorder; 4 Attention deficit hyperactivity disorder; * indicates obsessive compulsive 
disorder, oppositional defiant disorder, self-injury, tantrums, etc; Bold indicate categories that represent 50% or greater incidence within the literature. 
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et al. [16] 
De Kovel 



























0/2 2/8 8/23 0/7 14/56 2/16 0/2 0/2 6/6 13/83 4/5 1/2 0/3 0/1 57/216 (26) 
Cataracts 0/1 0/9 N/A 0/7 N/A 0/16 0/2 1/2 N/A N/A 0/3 0/2 0/3 1/1 2/46 (4) 
Congenital 
heart defect 
0/1 2/9 N/A 0/7 N/A 0/16 0/2 2/2 N/A N/A 0/3 0/2 0/3 0/1 4/46 (9) 
Genital 
abnormalities 
0/1 2/9 N/A 1/7 N/A 0/16 0/2 0/2 N/A N/A 0/3 0/2 N/A 0/1 3/46 (7) 
Recurrent 
infections 
0/1 2/9 N/A 0/7 N/A N/A 0/2 0/2 N/A N/A 0/3 0/2 N/A 0/1 2/30 (7) 
Ataxia/balance 
issues 
1/2 4/8 N/A 0/7 15/49 N/A 2/2 0/2 N/A N/A 0/3 0/1 0/3 0/1 22/78 (28) 
TE fistula 0/1 0/9 N/A 0/7 N/A 0/16 0/2 1/2 N/A N/A 0/3 0/2 0/3 0/1 1/49 (2) 
Hearing loss/ 
impairment 
0/1 1/9 N/A 0/7 N/A 1/16 0/2 0/2 N/A N/A 0/3 0/2 0/3 0/1 2/49 (4) 
Omphalocele 0/1 1/9 N/A 0/7 N/A 0/16 0/2 0/2 N/A N/A 0/3 0/2 0/3 0/1 1/49 (2) 
Abnormal 
brain imaging 
N/A 0/4 N/A 1/2 20/56 * 2/3 N/A N/A N/A N/A 5/5 1/2 3/3 N/A 32/75 (43) 
* indicates cases with insomnia, abnormal brain MRI or EEG, etc. 
 




The 15q11.2 BP1–BP2 microdeletion (Burnside-Butler) syndrome is now a recognized condition 
with over 200 individuals identified from the literature using chromosomal microarray analysis. 
Clinically, neurological dysfunction, developmental and language delay are the most commonly 
associated findings followed by motor delay, ADD/ADHD and autism spectrum disorder showing 
incomplete penetrance and variable expressivity. The four non-imprinted biallelically expressed genes 
(TUBGCP5, CFYIP1, NIPA1, NIPA2) in this microdeletion were initially noted to impact severity of 
clinical presentation and neurological impairment in two classical genomic imprinting disorders  
(i.e., Prader-Willi and Angelman syndromes) with typical 15q11–q13 deletions depending on the 
absence or presence of the genomic area between breakpoints BP1 and BP2 containing the four genes 
leading to studies recognizing this syndrome. The 15q11.2 BP1–BP2 microdeletion syndrome has a 
reported de novo frequency between 5%–22%, with 51% having inherited the microdeletion from an 
apparently unaffected parent and 35% having inherited the microdeletion from an affected parent. Low 
penetrance estimates may relate to subclinical manifestations of neuropsychiatric/behavioral problems or 
incomplete information about the parents of individuals with 15q11.2 BP1–BP2 microdeletion or 
members of control cohorts [44]. From reported patient cohorts presenting for genetic services and 
microarray analysis, this microdeletion syndrome can now be recognized as the most common 
cytogenetic abnormality found in autism spectrum disorder. 
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